secwatch.observer — SEC 8-K summary
======================================

Issuer:     KORU Medical Systems, Inc. (KRMD)
CIK:        0000704440
Form:       8-K
Filed at:   2026-05-06T23:59:59+00:00
Accession:  0001161697-26-000107
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KORU Medical Q1 revenue $11.8M (+22% YoY); net loss improves to $0.8M; FY guidance reiterated
--------------------------------------------------------------------------------

- Net revenue $11.8M, up 22% YoY; domestic core +11.7%, international core +35.2%, pharma services +166%.
- Gross profit $7.2M (+20% YoY); gross margin 61.5% vs 62.8% on tariff costs and production timing.
- Net loss improved 31% to $0.8M ($0.02 diluted EPS) from $1.2M ($0.03) in prior year.
- Cash $8.8M; cash usage $0.1M in Q1. Reiterates FY2026 revenue $47.5-50.0M, positive adjusted EBITDA & cash flow.
- Submitted 510(k) for Freedom Infusion System with deferoxamine; two pharma collaborations advanced to Phase III.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/704440/000116169726000107/0001161697-26-000107-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/704440/000116169726000107/form_8-k.htm
  HTML page:      https://secwatch.observer/filing/0001161697-26-000107

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer